The EU Chamber of Commerce has published a new report on China’s patent policies. Its author and the co-chair of the group’s IP working group tell Peter Leung how the country’s indigenous IP policies are hampering China’s goal of building breakthrough innovation capacity
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The Delhi High Court declined to stop Dr. Reddy’s from manufacturing Novo Nordisk’s drug, but will continue to hear the Danish company’s injunction application